MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways

World Journal of Gastroenterology

Volumn 21, Issue 5, 2015, Pages 1488-1497

  Gong, Bo ^a,b   Liu, Wan Wei ^a   Nie, Wen Jing ^c   Li, Dong Feng ^a   Xie, Zi Jun ^d   Liu, Chao ^a   Liu, Yan Hui ^a   Mei, Ping ^a   Li, Zi Jun ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Department of Radiology   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Colon cancer; MiR 21; RAS; RAS signaling pathways; RASA1

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; K RAS PROTEIN; MESSENGER RNA; PLASMID VECTOR; PROTEIN; RAF PROTEIN; RAS PROTEIN; KRAS PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; ONCOPROTEIN; RASA1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE CONTROL; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE MIR 21; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CACO 2 CELL LINE; COLON TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME FACTOR; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CACO-2 CELLS; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; P120 GTPASE ACTIVATING PROTEIN; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84922558715     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i5.1488     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96 [PMID: 18287387 DOI: 10.3322/CA.2007.0010]
2. Zhang YL, Zhang ZS, Wu BP, Zhou DY. Early diagnosis for colorectal cancer in China. World J Gastroenterol 2002; 8: 21-25 [PMID: 11833064]
3. Goh S. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer (Br J Surg 2012; 99: 1488-1500). Br J Surg 2013; 100: 1540 [PMID: 24037580 DOI: 10.1002/bjs.9267]
4. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol 2003; 14 Suppl 2: ii49-ii55 [PMID: 12810459 DOI: 10.1093/annonc/mdg730]
5. Lamas MJ, Duran G, Gallardo E. Anti-EGFR therapy in first-line colorectal cancer. Expert Rev Anticancer Ther 2011; 11: 1499-1503 [PMID: 21999123 DOI: 10.1586/era.11.149]
6. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113: 673-676 [PMID: 12809598 DOI: 10.1016/S0092-8674(03)00428-8]
7. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009; 10: 94-108 [PMID: 19148191 DOI: 10.1038/nrg2504]
8. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803 [PMID: 17072344 DOI: 10.1038/sj.onc.1210083]
9. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113-2129 [PMID: 16762633 DOI: 10.1053/j.gastro.2006.02.057]
10. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1915-1922 [PMID: 19276261 DOI: 10.1158/1078-0432.CCR-08-2545]
11. Ziyan W, Shuhua Y, Xiufang W, Xiaoyun L. MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol 2011; 28: 1469-1474 [PMID: 20480266 DOI: 10.1007/s12032-010-9563-7]
12. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061 DOI: 10.1056/NEJMoa0804385]
13. Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 2013; 13: 241-255 [PMID: 23281932 DOI: 10.1517/14712598.2012.756469]
14. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 2010; 9: 274-281 [PMID: 21208841 DOI: 10.3816/CCC.2010.n.040]
15. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961 [PMID: 18339877 DOI: 10.1158/0008-5472. CAN-07-5659]
16. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, Kanai F, Kawabe T, Omata M. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 2009; 136: 206-216 [PMID: 18992247 DOI: 10.1053/j.gastro.2008.09.063]
17. Wittinghofer A. Signal transduction via Ras. Biol Chem 1998; 379: 933-937 [PMID: 9792425]
18. Wittinghofer A, Scheffzek K, Ahmadian MR. The interaction of Ras with GTPase-activating proteins. FEBS Lett 1997; 410: 63-67 [PMID: 9247124 DOI: 10.1016/S0014-5793(97)00321-9]
19. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011; 54: 311-319 [PMID: 21067840 DOI: 10.1016/j.jhep.2010.06.036]
20. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta 2003; 1603: 47-82 [PMID: 12618308]
21. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, Zhang CY, Chen J, Zhang J. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem 2013; 288: 9508-9518 [PMID: 23322774 DOI: 10.1074/jbc.M112.367763]
22. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X. miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Exp Ther Med 2013; 6: 1265-1270 [PMID: 24223656]
23. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49: 1595-1601 [PMID: 19296468 DOI: 10.1002/hep.22838]
24. Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch Med Res 2011; 42: 281-290 [PMID: 21820606 DOI: 10.1016/j.arcmed.2011.06.008]
25. Kern HB, Niemeyer BF, Parrish JK, Kerr CA, Yaghi NK, Prescott JD, Gutierrez-Hartmann A, Jedlicka P. Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA Cell Biol 2012; 31: 1403-1411 [PMID: 22553926 DOI: 10.1089/dna.2011.1469]